omeprazole / Generic mfg. - LARVOL DELTA

Competence of omeprazole and chitosan nanoparticles as promising approaches for enhancing vegetative growth and leaf anatomical structure of plum under low nitrogen conditions. (PubMed, BMC Plant Biol) - No abstract available

Journal

Pharmacokinetic Effect of Y-3 on Repaglinide，Warfarin and Omeprazole in Healthy Participants (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Neurodawn Pharmaceutical Co., Ltd. | Recruiting ➔ Completed

Trial completion

Association of impaired medication adherence with subsequent clinical recognition of dementia or cognitive impairment in older veterans. (PubMed, Eur Geriatr Med) - "Among veterans without clinically recognized DCI, lower baseline medication adherence was associated with an increased risk for future clinically recognized DCI. Further studies should seek to disentangle whether low adherence is a risk factor for future DCI or an indicator of existing but not yet recognized DCI and whether this can inform clinical practice decisions."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Syringic acid protects against indomethacin-induced gastric injury via NF-κB and apoptotic pathway modulation. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Syringic acid may confer gastroprotective effects against indomethacin-induced gastric injury by modulating oxidative stress, inflammation, and apoptosis. While less potent than omeprazole, its multi-target actions suggest potential value as an adjunctive strategy for COX inhibitor-induced gastric damage."

IO biomarker • Journal • Inflammation • Peptic Ulcer • BAX • BCL2 • CASP3

Analysis of infection-related adverse events induced by proton pump inhibitors based on the FAERS and JADER databases. (PubMed, Medicine (Baltimore)) - "In the use of PPIs, we should pay attention to the occurrence of related adverse reactions, especially the damage to the infection-related adverse effects, monitor the relevant indicators, and take timely intervention measures to ensure the safety of medication."

Adverse events • Journal • Gastrointestinal Disorder • Infectious Disease • Pneumonia • Respiratory Diseases

Comparison between optimized bismuth quadruple therapy and standard clarithromycin-based triple therapy for first-line Helicobacter pylori eradication: a double-blind randomized controlled trial. (PubMed, Lancet Reg Health Am) - P4 | "We compared optimized bismuth quadruple therapy: esomeprazole 40 mg three times a day, amoxicillin 1 gr three times a day, metronidazole 500 mg three times a day, and bismuth subsalicylate 369 mg three times a day for 14 days, and standard triple therapy omeprazole 20 mg twice a day, amoxicillin 1 gr twice a day, and clarithromycin 500 mg twice a day for 14 days in a Chilean population. Optimized bismuth quadruple therapy is a reliable and safe empiric eradication therapy, especially in areas with high clarithromycin resistance. FONDECYT (1230504 AR); ANID-FONDAP (152220002 AR); Horizon 2020 program of European Union (825832 AR); ANID-FONDAP (15130011)."

Journal • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology • Peptic Ulcer • Solid Tumor • CYP2C19

Opportunities and challenges for the implementation of pharmacogenomics in supportive care for gastrointestinal cancer patients in Zimbabwe. (PubMed, Pharmacogenomics) - "PGX guidelines were fully implemented for tramadol, codeine, omeprazole, and ondansetron; partially for ibuprofen and celecoxib; and unimplementable for amitriptyline. There is an opportunity to improve supportive care in gastrointestinal cancer patients through pharmacogenomics though some specific medicines challenges to full implementations are due to limited registered medicines."

Biomarker • Journal • Gastrointestinal Cancer • Oncology • Solid Tumor

Successful Pregnancy Outcome in a Patient with Recurrent Miscarriage Due to PCOS Complicated by Hereditary Protein C Deficiency. (PubMed, Int J Womens Health) - "Our regimen comprises dydrogesterone for cycle regulation, rivaroxaban for PC deficiency-related thrombophilia, and metformin, amoxicillin, and omeprazole to manage PCOS-associated insulin resistance and chronic endometritis, with the aim of mitigating their contribution to impaired endometrial receptivity. Multi-disciplinary treatment (MDT) is crucial. Moreover, there are currently no international, evidence-based guidelines for the use of combined oral contraceptives (COCs) in PCOS complicated by hereditary thrombophilia, highlighting the urgent need for multicenter clinical studies to establish appropriate management strategies."

Journal • Cardiovascular • Endometriosis • Hematological Disorders • Pain • Polycystic Ovary Syndrome • Thrombosis • Venous Thromboembolism

A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjects (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

New P1 trial • Genetic Disorders • Obesity

Fibroblastic sleeve and short peripheral catheter failures: Impact of risk factors. (PubMed, J Vasc Access) - "Antibiotic infusion through short peripheral catheters was identified as a key risk factor for fibroblastic sleeve formation, while patient-related factors and specific therapies were associated with catheter failure. These findings underscore the importance of selecting and monitoring devices carefully in high-risk patients to minimize complications and enhance vascular access outcomes."

Journal • Diabetes • Infectious Disease • Metabolic Disorders • Oncology

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC) (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Providence Health & Services | Active, not recruiting ➔ Completed

Trial completion • Breast Cancer • Male Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2

High-Throughput Screening Using the Self-Controlled Tree-Based Scan Statistic to Identify Medications Associated With Hospitalization for Severe Acute Liver Injury. (PubMed, Pharmacoepidemiol Drug Saf) - "High-throughput screening using tree-based scan statistics detected potentially hepatotoxic drugs for investigation in future pharmacoepidemiology studies."

Journal • CNS Disorders • Gastroenterology • Hepatology • Liver Failure • Pain

Omeprazole-Mediated Nanodelivery of Copper for Synchronous Remodeling of Copper Influx and Efflux in Cuproptotic Glioblastoma Therapy. (PubMed, Acta Biomater) - "To improve the permeability across blood-brain tumor barrier (BTB), minoxidil sulfate (MS) and T7 peptide are modified on Cu-OME SNDs to produce Cu-OME/MS@T7 SNDs. Meanwhile, the released OME further blocks copper efflux by suppressing ATP7A copper efflux transporter. Collectively, this work demonstrates the effectiveness of OME-mediated copper delivery in inducing copper dyshomeostasis and triggering cuproptosis, highlighting a promising therapeutic approach through synchronous remodeling of copper influx and efflux."

Journal • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • ATP7A

To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: SpringWorks Therapeutics, Inc.

New P1 trial

Stress ulcer prophylaxis in non-critically ill patients: A cross-sectional survey in Saudi Arabia. (PubMed, Medicine (Baltimore)) - "This study presented the perspective of physicians regarding the main reasons for their use of SUP, along with factors significantly associated with this practice. Our findings indicate that there are opportunities to improve physician knowledge and empower interprofessional support to reduce inappropriate SUP use."

Journal • Gastroenterology • Stress Ulcer

Hydrogen sulfide reduces omeprazole and is oxidized to polysulfides and elemental sulfur. (PubMed, Free Radic Biol Med) - "Computational modeling revealed that the formation of the thioether is kinetically preferred over the formation of the disulfide. Overall, our results show that acid-activated omeprazole reacts with H2S forming the thioether derivative of omeprazole, polysulfides and elemental sulfur."

Journal

Evaluation of the Long-Term Administration of Proton Pump Inhibitors (PPIs) in the Mineral Nutrient's Bioavailability. (PubMed, ACS Omega) - "Rats were used as an animal model and divided into control and omeprazole-treated groups with subgroups based on treatment durations (10, 30, and 60 days)...Elemental analysis showed imbalances in Fe, Cu, and Ca levels in both the blood and organs. These findings suggest that prolonged PPI administration may negatively affect nutrient availability and physiological stability, highlighting the importance of further investigation into the nutritional consequences of long-term PPI use resulting in conditions such as microcytic anemia, bone malabsorption, and other issues related to mineral deficiency."

Journal • Hematological Disorders

Phyto-Mediated Zinc Oxide Nanoparticles from Raphanus sativus (L.): Metabolomic Insights, Gastroprotective Potential, and Docking-Supported Evidence. (PubMed, Life (Basel)) - "The ZnO-NPs at (200 mg/kg), showed superior efficacy over the extract and, in some cases, displayed equivalent or enhanced effects relative to the reference drug omeprazole. In silico findings support the gastroprotective potential of the plant by demonstrating strong binding associations for major phytochemicals. This paper highlights that green-synthesized ZnO-NPs exhibit a significant gastroprotective effect through the modulation of oxidative stress and inflammatory pathways, indicating their promise as a safe and effective alternative treatment for gastric ulcers."

Journal • Gastrointestinal Disorder • Inflammation • Peptic Ulcer • GAST • MMP10 • TNFA

Proton pump inhibitors and the risk of urolithiasis: A Mendelian randomization study. (PubMed, Medicine (Baltimore)) - "The genome-wide association studies (GWAS) of Omeprazole, Esomeprazole, Lansoprazole, and Rabeprazole medication can be obtained from GWAS catalog. In conclusion, our results suggest a causal relationship of PPIs to UL. For patients requiring antiacid therapy, esomeprazole may be a better option than Rabeprazole, especially in patients with high-risk factors for urolithiasis."

Journal • Renal Calculi • Urolithiasis

In Vivo Studies on the Interaction Between Orally Administered Nitrite and Omeprazole: Beyond Proton-Catalyzed S-Nitrosation. (PubMed, Antioxidants (Basel)) - "While omeprazole increased liver xanthine oxidoreductase (XOR), nitrite treatment attenuated this effect. These results demonstrate that oral nitrite treatment robustly elevates nitrite and RxNO concentrations in the liver, and these effects are associated with increased hepatic glutathione production and an upregulation of Mgst1 expression, counteracting the pro-oxidant effects induced by omeprazole."

Journal • Preclinical • MGST1

Ion-interference amplifier nano-system enhances radiotherapy via mitochondrial dysfunction and efferocytosis Inhibition. (PubMed, J Nanobiotechnology) - "This study presents a novel "ion-interference amplifier" strategy that concurrently enhances radiosensitization and immune response, offering a powerful model for synergistic radio-immunotherapy. Meanwhile, the integration of MRI-based tracking further underscores its potential for clinical translation."

Journal • Metabolic Disorders • Oncology

A Drug-Drug Interaction Study of EPX-100 (Clemizole Hydrochloride) With Clinical Probe Substrates for Selected CYP Enzymes (AES 2025) - P3 | "Each part was designed as a 2-period fixed sequence, with Parts 1 and 2 involving administration of a single oral 80-mg dose of EPX-100 on Day 1 (Period 1), followed in Period 2 by either 200-mg oral itraconazole twice daily for 1 day followed by 200-mg oral itraconazole once daily for 4 days (Part 1), or 100-mg oral phenytoin 3 times daily for 14 days (Part 2)...During Period 2, 80-mg twice-daily doses of EPX-100 were administered for 18 days with a single oral dose of 40-mg omeprazole, 2-mg midazolam, or 100-mg bupropion on Days 12, 14, and 15, respectively... The drug-drug interaction profile with EPX-100 has been evaluated, and final results will be presented. EPX-100 was generally safe and well tolerated in this study of healthy participants. Findings from this study will inform other studies of EPX‑100, including the currently enrolling ARGUS study for DS (NCT04462770) and the LIGHTHOUSE study for LGS (NCT05066217)."

Clinical • CNS Disorders • Epilepsy • CYP2C19 • CYP3A4

Serum level of (interleukin (IL)-2, IL-10, tumor necrosis factor (TNF)-a, motilin (MTL), gastrin (GAS), pepsinogen (PG), after adjunctive treatment in patients with chronic atrophic gastritis. (PubMed, J Med Biochem) - "The effective treatment rate in patients of TG post-treatment (92.73%) was higher than CG (78.18%) (P<0.05). Matrine combined with omeprazole enteric-coated tablets significantly improved gastric mucosal histopathology, reduced inflammatory cytokine levels, enhanced gastric function, and increased the H. pylori eradication rate compared to omeprazole monotherapy."

Journal • Gastrointestinal Disorder • Infectious Disease • Oncology • GAST • IL10 • TNFA

Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=28 | Recruiting | Sponsor: Institut de Recherches Internationales Servier (I.R.I.S.)

New P1 trial • Breast Cancer • Oncology • Solid Tumor

A systems biology approach to identify key targets in KRAS/BRAF-mutated colorectal cancer. (PubMed, Discov Oncol) - "This study sheds light on the molecular mechanisms of KRAS-mutated CRC, emphasizing IL1B as a prognostic marker. Among the identified therapeutic agents, Omeprazole demonstrated the strongest interaction with AHR, suggesting a potential for repurposing in CRC treatment, while IL1B-targeting inhibitors such as Canakinumab emerged as selective candidates for modulating tumor-promoting inflammation. Novel genes such as EPSTI1, COL20A1, CDH1, and SOX9 warrant further investigation."

Journal • Colorectal Cancer • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Solid Tumor • BRAF • CDH1 • EGF • EPSTI1 • IL1B • KRAS • SOX9